权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Southeast Cancer Control Consortium, Inc

东南癌症控制联盟有限公司

基本信息

批准号：
8540920
负责人：
James Norman Atkins
金额：
$ 187.49万
依托单位：
SOUTHEAST CLINICAL ONCOL RES CONSORTIUM
依托单位国家：
美国
项目类别：
财政年份：
1987
资助国家：
美国
起止时间：
1987-07-01 至 2014-12-19
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8540920
关键词：
African American Applications Grants Area Cancer Control Clinical Research Associate Clinical Trials Communities Community Clinical Oncology Program Continuing Education Development Early Diagnosis Electronic Mail Female Funding Gender Goals Grant Guidelines Incidence Individual Institution Institutional Review Boards Knowledge Mails Malignant Neoplasms Medical Minority Groups Mission Monitor Morbidity - disease rate National Cancer Institute Office for Human Research Protections Oncologic Nursing Oncology Nurse Participant Patients Physicians Population Population Density Preparation Prevention education Protocols documentation Regulation Reporting Research Rural Community Site Visit Telefacsimile Telephone Training Underserved Population Woman anticancer research base cancer therapy data management demographics ethnic minority population implementation trial improved mortality operation programs socioeconomics web site

项目摘要

DESCRIPTION (provided by applicant): The Southeast Cancer Control Consortium, Inc. (SCCC), CCOP has been funded by the National Cancer Institute (NCI) since 1987. The SCCC is a consortium of 20 components/24 institutions in a five-state area of the southeast. The SCCC's long-term objective is to bring state-of-the-art clinical trials to an arena of community institutions to increase access. The catchment of the referral communities is estimated at 8.4 million, with demographics reflecting a low population density, limited socioeconomic and educational development, female percentage greater than 50%, and ratio of African American to white population almost twice the national average. There are 155 participating physicians. Each component has a designated "Community Leader" (CL) and "Study Coordinator" (SC) responsible for coordination of the program among participating physicians and the research team. The research team is comprised of oncology nurses and clinical research associates (CRAs) trained by the SCCC Operations Office in compliance to federal and research base (RB) regulations. The SCCC Operations Office coordinates the activities by providing: telephone/fax/email information; website that supplies documents and queries for RBs; Institutional Review Board (IRB) approvals monitoring; RB protocol semimonthly mailings; conduction of component on-site visits; data management training/continuing education programs; preparation of grant applications and reports; and coordination of RB audits. The SCCC Operations Office provides the components with clinical trials from eight RBs. Each component determines the studies applicable to their area and the local IRB, which is authorized by the Office for Human Research Protections (OHRP), grants approval. The CLs and SCs educate and facilitate trial implementation. The expansive network supplies physicians' access to the most advanced level of cancer programs, so patients/participants may access current options. The goal is to reduce morbidity and mortality of cancer by overcoming ethnic, minority, gender, and socioeconomic barriers to clinical trial participation through increasing the number of physicians participating in cancer research with compliance maintained in protocol guidelines.

描述（由申请人提供）：东南癌症控制联盟，公司。自1987年以来，CCOP一直由国家癌症研究所（NCI）资助。SCCC是一个由东南部五个州的20个组成部分/24个机构组成的联盟。SCCC的长期目标是将最先进的临床试验带到社区机构的竞技场，以增加获得性。转诊社区的覆盖范围估计为840万人，人口统计反映出人口密度低，社会经济和教育发展有限，女性比例超过50%，非洲裔美国人与白色人口的比例几乎是全国平均水平的两倍。共有155名医生参加。每个组成部分都有一名指定的“社区领导人”（CL）和“研究协调员”（SC），负责协调参与医生和研究团队之间的计划。研究团队由肿瘤科护士和临床研究助理（CRA）组成，由SCCC运营办公室按照联邦和研究基地（RB）法规进行培训。SCCC运营办公室通过以下方式协调活动：提供电话/传真/电子邮件信息;为RB提供文件和查询的网站;机构审查委员会（IRB）批准监测; RB方案半月邮件;进行组件现场访视;数据管理培训/继续教育计划;准备拨款申请和报告;以及协调RB稽查。SCCC运营办公室为这些组件提供来自八个RB的临床试验。每个组成部分确定适用于其区域的研究，并由人类研究保护办公室（OHRP）授权的当地IRB批准。社区联络员和社区联络员负责教育和促进试验性实施。这个庞大的网络为医生提供了最先进的癌症项目，因此患者/参与者可以访问当前的选项。其目标是通过增加参与癌症研究的医生数量并遵守方案指南，克服参与临床试验的种族、少数民族、性别和社会经济障碍，降低癌症的发病率和死亡率。

项目成果

期刊论文数量（14）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.

诱导紫杉醇/卡铂随后同步放化疗治疗不可切除的 III 期非小细胞肺癌：一项有限访问研究 - CALGB 9534。

DOI：
10.3816/clc.2005.n.021
发表时间：
2005
期刊：
Clinical lung cancer
影响因子：
3.6
作者：
Akerley,Wallace;HerndonJr,JamesE;Lyss,AlanP;Choy,Hak;Turrisi,Andrew;Graziano,Stephen;Williams,Todd;Zhang,Chunfeng;Vokes,EverettE;Green,MarkR
通讯作者：
Green,MarkR

Combination cisplatin and carboplatin in advanced squamous cell carcinoma of the head and neck.

顺铂和卡铂联合治疗晚期头颈部鳞状细胞癌。

DOI：
10.3109/07357909609018883
发表时间：
1996
期刊：
Cancer investigation
影响因子：
2.4
作者：
Patton,JF;Powell,BL;White,DR;Russell,GB;Inabinet,RT;Muss,HB
通讯作者：
Muss,HB

Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902.

通过胸膜灌洗获得的细胞中人端粒酶逆转录酶 mRNA 的检测与 I/II 期非小细胞肺癌患者的较差预后无关：来自癌症和白血病组 B 159902 的结果。

DOI：
10.1016/j.jtcvs.2012.08.059
发表时间：
2013
期刊：
The Journal of thoracic and cardiovascular surgery
影响因子：
0
作者：
Boylan,AliceM;Wang,XiaofeiF;Ko,Richard;Watson,PatriciaM;Gu,Lin;Harpole,David;Bueno,Raphael;Kelly,Rosemary;Kohman,Leslie;Kratzke,Robert
通讯作者：
Kratzke,Robert

Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association.

长春新碱联合高剂量依托泊苷治疗晚期乳腺癌：皮埃蒙特肿瘤学协会的一项 II 期试验。

DOI：
10.1007/bf00686641
发表时间：
1994
期刊：
Cancer chemotherapy and pharmacology
影响因子：
3
作者：
Thomas,GW;Muss,HB;Jackson,DV;McCulloch,J;Ramseur,W;McFarland,J;Hoen,H;Pavy,M;Heath,R
通讯作者：
Heath,R

Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment].

老年转移性乳腺癌的化疗。